Publications by authors named "S L Linn"
Article Synopsis
- The oestrous cycle significantly affects breast cancer's response to neoadjuvant chemotherapy (NAC), with treatment during the dioestrus stage resulting in less effectiveness compared to the oestrus stage.
- In mouse models and human premenopausal cohorts, dioestrus is associated with increased chemoresistance, characterized by more cells undergoing epithelial-to-mesenchymal transition, narrower tumor blood vessels, and higher macrophage levels.
- Understanding the impact of the oestrous cycle on treatment response could lead to improved timing for chemotherapy, enhancing patient outcomes.
Background: Oligometastatic breast cancer (OMBC) is a clinical entity with a prospect of long-term survival, but uncertainty remains on its optimal treatment. We studied whether intensified alkylating chemotherapy (IACT) improves long-term outcome compared to conventional-dose chemotherapy (CDCT) as part of a multimodality approach for patients with OMBC harboring homologous recombination deficiency (HRD).
Patients And Methods: Eligible patients had HER2-negative OMBC, harboring HRD, with ≤ 3 distant metastases, pathologic proof of distant disease and a favorable response to three cycles CDCT.
Decisions are often made by heterogeneous groups of individuals, each with distinct initial biases and access to information of different quality. We show that in groups of independent agents who accumulate evidence the first to decide are those with the strongest initial biases. Their decisions align with their initial bias, regardless of the underlying truth.
View Article and Find Full Text PDFArticle Synopsis
- Young women with breast cancer have a higher likelihood of carrying harmful BRCA gene variants, but data on tumor histology's prognostic value is limited.
- A study involving 4,628 patients revealed that lobular tumors are generally diagnosed at a later stage and are more often linked to BRCA2 mutations, while ductal tumors are frequently associated with BRCA1 mutations.
- Despite differences in tumor characteristics and treatment approaches, the study found no significant differences in disease-free or overall survival between those with ductal and lobular tumors, indicating that histology may not influence prognosis.
Article Synopsis
- Immune checkpoint inhibition (ICI) combined with chemotherapy is the standard treatment for stage II-III triple-negative breast cancer, but the effectiveness of ICI alone remains unclear.
- The adaptive BELLINI trial found that short-term ICI treatments led to immune activation in a significant portion of patients, correlating immune response with tumor-infiltrating lymphocytes.
- A new cohort is being studied with patients who have high levels of these lymphocytes; early results show a notable rate of major and complete pathological responses post-treatment, suggesting that neoadjuvant ICI could be a promising approach without chemotherapy.